Parkinson's disease is characterized by a loss of dopaminergic neurons in a specific brain region, the ventral midbrain. Parkinson's disease is diagnosed when about 50% of the dopaminergic neurons of the substantia nigra pars compacta (SNpc) have degenerated and the others are already affected by the disease. Thus, it is conceivable that all therapeutic strategies, aimed at neuroprotection, start too late. Therefore there is an urgent medical need to discover new pharmacological targets and novel drugs with disease-modifying properties. In this regard, modulation of endogenous adult neurogenesis towards a dopaminergic phenotype may provide a new strategy to target Parkinson's disease by partially ameliorating the dopaminergic cell loss that takes place in this disorder. We have previously shown that a PDE7 inhibitor called S14 exerts potent neuroprotective and anti-inflammatory effects in different rodent models of Parkinson's disease indicating that this compound could represent a novel therapeutic agent to stop the dopaminergic cell loss that takes place during the progression of the disease. In this paper we show that, in addition to its neuroprotective effect, the PDE7 inhibitor S14 is also able to induce endogenous neuroregenerative processes towards a dopaminergic phenotype. We here describe a population of actively dividing cells, which give rise to new neurons in the SNpc of hemiparkinsonian rats after treatment with S14. In summary, our data identify S14 as a novel regulator of dopaminergic neuron generation.
Introduction
Parkinson's disease (PD) is a chronic and progressive neurodegenerative disorder characterized by motor symptoms (muscular rigidity, resting tremor and bradykinesia or slowness of movement), and non-motor symptoms (visual hallucinations and dementia) [1] .The hallmark of PD is the gradual loss of dopamine-producing neurons, dopaminergic neurons, in a specific brain region, the ventral midbrain [2] .Although the selective loss of dopaminergic neuron within the substantia nigra pars compacta (SNpc) is the pathological characteristic of this disease, cell loss also takes place in other brain areas such as the locus coeruleus and dorsal nuclei of the vagus, among others [3] .The underlying cause of dopaminergic cell death and the mechanisms implicated remain elusive. Due to the slowly progressive way of this neurodegenerative process [4] , PD is usually diagnosed when more than 50% of dopaminergic neurons of the SNpc have already degenerated and the others are affected by the disease. Since, so far, there are not treatments available that prevent the development of PD or modify its detrimental course ("disease-modifying agents"), and the ones used are only palliative and only leads to temporary improvement of the symptoms, there is an urgent medical need to discover new therapeutic strategies for PD which could slow, halt, or reverse the disease process.
Phosphodiesterases (PDEs) comprise a family of 21 members, which have been so far classified into 11 groups, according to their sequence homology, cellular distribution, and sensitivity to different PDE inhibitors [5, 6] , being some of them expressed in the central nervous system [7] . PDE7 is a cAMP-specific PDE [5, 8] and it has been recently demonstrated that can be a target for the control of neuroinflammation [9] . PDE7 inhibition has recently emerged as a good therapeutic option for the treatment of Page 4 of 44 5 different neurodegenerative diseases. Several studies from our group have shown that different inhibitors of PDE7 are potent neuroprotective and anti-inflammatory agents in some animal models of neurodegenerative disorders, including PD [10] [11] [12] [13] . Very recent data from our group show that PDE7 depletion in the SNpc, using specific shRNAs for PDE7, significantly protects dopaminergic neurons and improves motor function in LPS and 6-OHDA lesioned mice [14] .
The ability of the adult central nervous system to produce new neurons is limited, rendering the brain particularly vulnerable to injury and disease. In mammals, the majority of neurons are born by the prenatal period, but it is well established that neurons continue to arise in two niches of the adult brain, the subventricular zone (SVZ) of the lateral ventricle and the subgranular zone (SGZ) of the dentate gyrus of the hippocampus [15, 16] . The generation of new neurons in these regions may contribute to endogenous repair mechanisms after brain damage and/or chronic disease [17] . It is known that dopamine regulates adult neurogenesis in the SVZ and hippocampus in rodents and human, and a decrease in new stem cell proliferation has been described in PD (review in: [18] ). It has been shown a decreased proliferation of neural stem cells (NSCs) in the subventricular zone of human PD brains, and in two animal models of PD: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 6-hydroxydopamine (6-OHDA) [19] [20] [21] , as a consequence of dopamine depletion caused by the loss of dopaminergic neurons in the SNpc. Consequently various therapeutic approaches, besides the classical use of dopaminergic agents, are now aimed at manipulating the resident stem/progenitor cells to produce neuroblasts, which could eventually differentiate into dopaminergic cells. The potential of this strategy, inducing endogenous neurogenesis by means of new therapeutic agents, holds great promise 6 since this increased neurogenesis could help to replace the dopaminergic cells lost in PD, which is already present by the time a patient is diagnosed.
The aim of the present study was to investigate the effects of the PDE7 inhibitor S14, on adult neurogenesis in the 6-OHDA model of PD mimicking a severe dopaminergic striatal deficit. Here, we show that pharmacological manipulation of PDE7 in vivo induces a strong neurogenesis in the SNpc of 6-OHDA-lesioned animals towards a dopaminergic phenotype. In vitro, PDE7 inhibition increased the neuronal differentiation of neurospheres obtained either from embryonic ventral midbrain or adult SVZ. Then, by using PDE7 inhibitors, we could potentially contribute to upregulate endogenous neurogenesis, and/or favor integration of new dopaminergic neurons to stimulate neurorepair in PD.
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Materials and Methods.
Animals. Adult male Wistar rats (8-12 weeks old) were used in this study. All procedures with animals were specifically approved by the "Ethics Committee for Animal Experimentation" of the Instituto de Investigaciones Biomedicas (CSIC-UAM) and carried out in accordance with the protocols issued, which followed National (normative 1201/2005) and International recommendations (normative 86/609 from the European Communities Council). Adequate measures were taken to minimize pain or discomfort of animals.
Embryonic mesencephalic precursor isolation. Cultures were derived from the ventral mesencephalon (VM) of rat embryos at embryonic day 14 as previously described [10] . Leiden, The Netherlands) for 45 min at 37 °C. Later on, images were obtained using a LSM710 laser scanning spectral confocal microscope (Zeiss). Confocal microscope settings were adjusted to produce the optimum signal-to-noise ratio. Primary antibodies were directed against the following: β-III-tubulin (TuJ-1 clone; rabbit; Abcam), MAP-2 (mouse; Sigma), Nurr1 (rabbit; Sta. Cruz) and tyrosine hydroxylase (rabbit; Millipore).
Staining of nuclei was performed using 4′,6-Diamidino-2-phenylindole (DAPI).
Neurogenic studies in vivo. To determine the neurogenic effects of S14 in a model of dopaminergic cell loss, the animals were properly anesthetized and placed in a Rotation behavior analysis. Animals were tested for apomorphine-induced contralateral rotations as previously described [10, 14] . Briefly, thirty days after unilateral 6-OHDA injection into the Striatum, apomorphine (Sigma, Spain) was subcutaneously administered at 0.5 mg/kg. After apomorphine injection, the rats were individually set into a hemispherical glass bowls (diameter 20 cm). Starting 10 min after apomorphine application, the numbers of full contralateral rotations were monitored for 40 min.
Analysis of completed (360°) rotations was made offline and expressed as the number of contralateral net turns per minute. Three different experiments with at least 12 animals/experimental group were performed.
Statistics Analysis. Statistical comparisons for significance were performed by ANOVA using the SPSS statistical software package (version 20.0) for Windows (Chicago, IL)
followed by Newman-Keuls' test. Differences were considered statistically significant at p < 0.05.
Page 12 of 44
Results
Effect of PDE7 inhibition on the levels of PDE7 and P-CREB in neurosphere cultures.
We first performed Western blot analysis to determine the levels of PDE7 and CREB phosphorylation in vitro, using neural progenitors isolated from the embryonic ventral mesencephalon (VM). The progenitor cells divide forming small proliferating neurospheres (NS), visible after 3 days in culture. Since PDE7 comprises two genes, PDE7A and PDE7B, both isoforms were analyzed. As shown in Figure 1A , both isoforms were expressed in VM-derived NS, being the levels of PDE7B more prominent than that of PDE7A. No effect of S14 or BRL50481 (a commercially available PDE7 inhibitor used as standard reference) on PDE7 A and B expression was observed. We next examined the effects of S14 and BRL50481 on the phosphorylation levels of the cAMP response element binding protein (CREB), a well-known target of the cAMP signaling pathway, in order to confirm that effectively the S14 compound is acting through inhibition of PDE7 and subsequent induction of the cAMP pathway. To analyze this, NS cultures were treated or not with BRL50481 or S14 for 7 days and the phosphorylation of CREB was determined. The results presented in Figure 1B clearly show that treatment of NS with BRL50481 or S14 promoted a significant increase in the levels of P-CREB.
PDE7 inhibition induces proliferation and growth of embryonic ventral mesencephalic-derived neurospheres.
Next, we analyzed whether S14 affected neural stem cell proliferation of NS cultures.
To assess the involvement of PDE7 inhibition in neurosphere formation, NS were cultured in floating conditions on non-adhesive dishes and cultured for 7 days in the To investigate whether BRL50481 and S14 influenced neuronal differentiation after adhesion of NS, we analyzed by immunocytochemistry the expression of two neuronal markers, β-III-tubulin (a classical marker of immature neurons) and MAP-2 (a marker of more mature neurons). To this end, NS treated with BRL50481 or S14 during 7 days
were adhered to a substrate and allowed to differentiate for 3 days, afterwards immunocytochemical analysis using specific antibodies were performed. Some cultures were used for Western blot analysis and quantification of protein levels.
Immunocytochemical analysis showed no differences in β-III-tubulin expression between controls and treated cultures (Fig. 3) Taking into account the potential neurogenic effect of PDE7 inhibition, we next investigated whether treatment with the PDE7 inhibitors BRL50481 and S14 could specifically promote the differentiation of NS towards dopaminergic neurons. For this purpose, we analyzed the expression levels of Nurr1 (a marker of dopaminergic precursors) and TH (the rate-limiting enzyme in dopamine synthesis and marker of dopaminergic neurons) in NS cultures derived from both embryonic midbrain and adult SVZ. NS treated or not with BRL50481 or S14 during 7 days were adhered to poly-Llysine-coated plates and allowed to differentiate for 3 days, afterwards immunocytochemical and Western blot analysis using specific antibodies were performed. The results presented in Figure 4A show that, the number of Nurr1-and THpositive stained cells in embryonic VM cultures is greatly increased in those cultures treated either with BRL50481 or S14 compounds, with respect to controls. Furthermore, this increase was also observed in NS cultures derived from a well-established adult neurogenic niche, the SVZ ( Figure 4B ). These results clearly indicate that PDE7 To analyze in vivo neurogenesis, adult rats were lesioned with 6-OHDA and 15 days later received a daily oral dose of S14, which is known to cross the blood brain barrier [13, 26] during another 15 days, following the experimental approach shown in Figure   5A . Rats were also intraperitoneally injected with BrdU. To test whether neurons are generated in the SNpc after S14 treatment, coronal sections containing the SNpc were doubled-immunostained using anti-TH and anti-BrdU specific antibodies. Vehicletreated animals presented BrdU + cells throughout the entire SNpc (Fig. 5B) elicited by S14 in the SNpc, a parallel increase in TH staining was observed in the striatum of treated animals ( Figure 5C ). Concerning neuroinflammation, an event that takes place after a brain injury, we observed a significant reduction in glial activation (astrocytes and microglial cells) in those animals lesioned with 6-OHDA and treated with S14 (Supplementary Figure 1) . Taking into account these results, we next studied whether the new generation of dopaminergic cells in the SNpc together with the reinnervation observed in the striatum and the anti-inflammatory effect of S14 was associated with an improvement of the motor alterations induced by 6-OHDA-injection.
To this end, 30 days after lesion rats were tested for apomorphine-induced contralateral rotations. Apomorphine subcutaneous administration induces contralateral rotational behavior in denervated animals. Our results clearly show a significant increase in the number of contralateral turns per minute following apomorphine administration in 6-OHDA-lesioned animals ( Fig. 5D ), compared with control animals. S14 administration led to substantial attenuation of the asymmetric motor behavior in lesioned animals. DCX is a microtubule-associated protein, which is a valuable endogenous marker for dividing neuroblasts and immature neurons [32, 33] . The results shown in Figure 5E indicate the presence of nestin and DCX-labeled cells in the SNpc of vehicle-and 6-OHDA-injected animals. The presence of nestin-positive cells suggest that, as indicated by other authors, the SNpc of adult animals can also contain neural precursor cells. This
The newborn cells found in the
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Figure also show that rats lesioned with 6-OHDA and treated with S14 presented an increase in the number of nestin-positive cells. Also the number of cells expressing DCX was increased in the S14-treated group of animals.
It is known that PDE7 inhibition increases cAMP levels, consequently we next analyzed the phosphorylation state of CREB, a well-known target of the cAMP signaling pathway. The results shown in Figure 6 clearly indicate that S14 oral administration increases the levels of phospho-CREB in the SNpc in this animal model of PD.
Immunodetection of total amount of CREB protein was used as a control of the phosphorylation state induction.
S14 increases the number of nestin + cells in the mesencephalic aqueduct and induces proliferation and differentiation of adult progenitor cells in vivo in the SVZ.
As commented above, the newborn cells found in the SNpc could also originate from precursors present in other brain areas such as the mesencephalic aqueduct and that could have migrated to the SNpc, as it has been suggested before [27, 34] . Also, there are several reports showing an impaired neurogenesis in the SVZ in PD patients and in several animal models of this disease. Consequently, we finally analyzed the presence of possible neural progenitor cells (NPC) in both regions ( Figure 7 ). Figure 7A shows that S14 treatment considerably increased the number of Nestin-positive cells in the mesencephalic aqueduct of rats lesioned with 6-OHDA and treated later with S14, in comparison with control vehicle-treated animals. In the SVZ, S14 treatment considerably increased the number of Nestin/BrdU double-stained cells ( Figure 7B ).
These results suggest that S14 stimulates the proliferation of new progenitors in the mesencephalic aqueduct and in the SVZ of adult rats. We also analyzed the presence of DCX-stained cells in this neurogenic niche. As shown in Figure 7C , the increase in proliferating cells in the SVZ after S14 treatment correlates with a notably increase in the number of DCX + cells in this area. An increase in the migrating chain of cells was also observed.
Discussion
Similar to other neurodegenerative diseases, PD is diagnosed when more than 50% of value is largely questioned by data from transplanted patients, which indicate that the grafted neurons have compromised function and eventually acquire disease [36] [37] [38] [39] [40] .
Another approach to achieve clinical benefit is an indirect way by activating precursor cells that are already present in the brain. In the present study we have investigated the potential effect of PDE7 inhibition on the promotion of dopaminergic cells in the 6-OHDA animal model of PD. Our results demonstrate a unique role for the PDE7 inhibitor S14 as a regulator of dopamine precursor cell proliferation and differentiation in the SNpc of 6-OHDA-lesioned adult rats, which could have potential implications for future innovative therapies in PD.
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Previous work from our group has shown that the PDE7 inhibitor S14 significantly protects dopaminergic neurodegeneration and improves motor function in LPS-lesioned animals [10] . We here show that S14 regulates the expansion and differentiation of the stem cell population derived from VM. This is evident in vitro by an enhanced number and size of neurospheres and an induction of MAP2-positive cells. More interestingly we also found a significant increase in the number of Nurr1-and TH-positive cells, indicating that the S14 compound can elicit differentiation of VM stem cells towards a dopaminergic phenotype. We also observed an increase in Nurr1-and TH-labeled cells in the NS cultures derived from the SVZ of adult rats treated with the compound.
Our work shows that PDE7 inhibition by S14 has a dual function in neural stem cells:
induction of proliferation and differentiation, and suggests that this compound is not only mitogen for neural stem cells, but is also an inducer of neuronal differentiation. It seems interesting that inhibition of PDE7 can promote both proliferation and differentiation. However, precedents for this phenomenon are seen in other cases, such as leukotriene B4 [41] , mild hypoxia [42] , BMPs [43] , EGF/FGF2 [44] , NGF/BDNF/bFGF [45] , and the transcription factors Lmx1a and Lmx1b [46] . In this respect, we suggest that inhibition of PDE7 can represent a new strategy for restoring neurogenesis.
The mechanism of action of this compound seems to be an inhibition of PDE7, the CREB plays a considerable role in adult neurogenesis [47] , particularly in the hippocampus [48, 49] . Our results add new and important data suggesting that activation of CREB following PDE7 inhibition results in a generation of new neurons with a dopaminergic phenotype.
Several studies have suggested that neurogenesis in the SVZ is impaired in PD, which might be due to the lack of dopamine in the subventricular zone [19, 20, 50 ]. An It has been shown that in adult humans new neurons integrate in the striatum, which is adjacent to the SVZ niche [53] . It is known that in the SVZ of humans there is a generation of neuronal precursors, however, unlike rodents, these new neurons are not added in the olfactory bulb of adult humans [54, 55] . This fact, poses the question of whether neuroblasts may migrate to another location close to the ventricle, e.g. the striatum. Our data suggest that the newly generated neurons found in the SNpc of adult rats after S14 treatment may originate from the SVZ, as described in humans. In line with this notion there are data showing that, although the vast majority of neurons generated in the SVZ in rodents integrate in the olfactory bulb, also a number of striatal neurons are generated from the SVZ in both rodents and monkeys following a stroke [56] [57] [58] .
Although some of the newly generated neurons found in the SNpc can be generated in the SVZ, other origins cannot be excluded. In this regard, the presence of progenitor cells in non-neurogenic regions, such as the cortex, septum, spinal cord, ventricular extension and the SN has also been demonstrated, but at a less appreciable level compared with the established neurogenic regions [59] . We here report that cells expressing the uncommitted neural precursor marker nestin are present not only in the SVZ but also in the SNpc and in the midbrain aqueduct. In a similar way we have found DCX + cells, marker associated to dividing neuroblasts, in the SNpc after treatment with S14. We furthermore report a significant increase in the SNpc neurons in rats lesioned with 6-OHDA after treatment with S14. Similar results were previously reported by others, describing the presence of dopaminergic neurons with BrdU-positive nuclei in the SNpc, suggesting that these cells could have migrated from the midbrain aqueduct or arise from precursors already existing in the SNpc [34, 60, 61] . However other authors have not been able to reproduce these results and the occurrence of neurogenesis in the SNpc still remains controversial [18, 27] . These discrepancies among the different studies could be due to the different methodologies used. Our findings suggest that the new generated dopaminergic cells, in response to the S14 treatment, can originate from 
Conclusion
Together, these observations suggest that PDE7 inhibition may represent a means of replacing neurons lost in the SNpc of PD patients and consequently could confer therapeutic benefit in this disease. In this regard, the PDE7 inhibitor S14 holds great promise as a therapeutic new strategy for PD since this compound, besides inducing replacement of dopaminergic neurons, is also able to induce a significant neuroprotection of the remaining cells. 
